Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35216385)

  • 1. VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor.
    Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; D'Orazi G; Cirone M
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53.
    Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; Maretto M; Bassetti E; Caiazzo R; D'Orazi G; Cirone M
    Exp Cell Res; 2021 Nov; 408(2):112879. PubMed ID: 34653407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.
    Valdez BC; Tsimberidou AM; Yuan B; Nieto Y; Baysal MA; Chakraborty A; Andersen CR; Andersson BS
    Oncotarget; 2024 Jun; 15():361-373. PubMed ID: 38829622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells.
    Raineri A; Prodomini S; Fasoli S; Gotte G; Menegazzi M
    Biochem Pharmacol; 2019 Sep; 167():173-181. PubMed ID: 31185226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
    PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replication.
    Arena A; Gilardini Montani MS; Romeo MA; Benedetti R; Gaeta A; Cirone M
    Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119168. PubMed ID: 34728235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    Cho HY; Kim YB; Park WH; No JH
    Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
    Bagnolini G; Milano D; Manerba M; Schipani F; Ortega JA; Gioia D; Falchi F; Balboni A; Farabegoli F; De Franco F; Robertson J; Pellicciari R; Pallavicini I; Peri S; Minucci S; Girotto S; Di Stefano G; Roberti M; Cavalli A
    J Med Chem; 2020 Mar; 63(5):2588-2619. PubMed ID: 32037829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells.
    Sargazi S; Saravani R; Zavar Reza J; Zarei Jaliani H; Galavi H; Moudi M; Abtahi NA
    Iran Biomed J; 2019 Sep; 23(5):312-23. PubMed ID: 31102368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Guibbal F; Hopkins SL; Pacelli A; Isenegger PG; Mosley M; Torres JB; Dias GM; Mahaut D; Hueting R; Gouverneur V; Cornelissen B
    Mol Imaging Biol; 2020 Oct; 22(5):1226-1234. PubMed ID: 32342268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
    Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
    Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
    Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
    Meneceur S; De Vos CE; Petzsch P; Köhrer K; Niegisch G; Hoffmann MJ
    J Cell Mol Med; 2024 May; 28(9):e18342. PubMed ID: 38693852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.